Recent political commentary from Donald Trump regarding GLP-1 medications has generated significant friction among medical professionals and patients. While the former president has taken actions aimed at reducing the costs of these drugs, his habit of referring to them as "fat shots" or "fat drugs" is drawing criticism for its tone. Medical experts note that this terminology is inaccurate and stigmatizing. These prescriptions are FDA-approved to treat Type 2 diabetes, insulin resistance, and conditions like sleep apnea, while also showing benefits for heart health.
Patients report that these medications are life-changing, providing relief for metabolic issues that did not respond to traditional diet and exercise. Physicians point out that the framing of these drugs as vanity tools ignores their clinical role in managing chronic health conditions. Instead of using derogatory nicknames, many in the medical community argue that policy efforts should remain focused on improving insurance coverage, including through Medicaid, so that patients in need can access these treatments without financial barriers.
Advocates for health equity emphasize that obesity is a complex, chronic condition influenced by environmental and structural factors rather than individual moral failure. By labeling these treatments with insulting terms, the discourse shifts toward shame, which discourages patients from seeking necessary care. The consensus among those currently taking GLP-1s is clear: they are tools to restore health and quality of life. Patients say the impact of the medicine outweighs the political rhetoric used to describe it.